Bronchiolitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bronchiolitis – Drugs In Development, 2024 report and make more profitable business decisions.
Bronchiolitis is inflammation of the small airways in the lungs. It is the most common lower respiratory tract infection in pediatric patients between 1 month and 2 years of age. It is usually caused by the respiratory syncytial virus (RSV) and is characterized by inflammation, edema, and necrosis of the bronchiole’s epithelium. It is transmitted by air droplets. symptoms of bronchiolitis include fever, cough, dyspnea, and Nasal discharge.
The Bronchiolitis drugs in development market research report provide comprehensive information on the therapeutics under development for Bronchiolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiolitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bronchiolitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bronchiolitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bronchiolitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bronchiolitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adare Pharma SolutionsBeijing Tri-Prime Genetic Engineering Co Ltd
Boehringer Ingelheim International GmbH
Enzyvant Sciences Ltd
F. Hoffmann-La Roche Ltd
Koutif Therapeutics LLC
Mereo Biopharma Group Plc
Novartis AG
OrphAI Therapeutics Inc
Renovion Inc
SolAeroMed Inc
Trove Therapeutics Inc
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bronchiolitis reports